I-Mab Biopharma Company
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics. I-Mab Biopharma is developed TJM2, a neutralising antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug targets the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for acute and chronic inflammation.
The company will commence development after receiving approval for the Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA).
Headquarters:
China
Funding Status:
N/A
Employee Number:
N/A
Investment Stage:
N/A
Number Of Exists:
N/A
Technology:
COVID
Investor Type:
N/A
Founded Date:
N/A
Industry:
Vaccine/Drug